Whitehawk Therapeutics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Whitehawk Therapeutics stock has a consensus rating of "Buy" and an average price target of $6.50. The average 1-year stock price forecast is 47.06% higher than the current stock price, while the lowest is $4.00 (-9.50%) and the highest is $8.00 (+81.00%).

Price Target: $6.50 (+47.06%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.00	$6.50	$7.00	$8.00
Change	-9.50%	+47.06%	+58.37%	+81.00%

* Price targets were last updated on May 22, 2026.

Analyst Ratings

The average analyst rating for Whitehawk Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	1	2	2	2	2	2
Buy	0	0	0	1	1	1
Hold	3	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	5	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Boris Peaker JonesTrading	JonesTrading	Buy Maintains $7	Buy	Maintains	$7	+58.37%	May 22, 2026
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $6 → $7	Buy	Reiterates	$6 → $7	+58.37%	May 8, 2026
Tara Bancroft TD Cowen	TD Cowen	Hold Maintains n/a	Hold	Maintains	n/a	n/a	May 7, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Apr 21, 2026
Reni Benjamin Citizens JMP	Citizens JMP	Buy Initiates $8	Buy	Initiates	$8	+81.00%	Apr 16, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 7.15M

-100.00%

from 7.15M

Revenue Next Year

n/a

EPS This Year

-1.17

from -1.74

EPS Next Year

-1.23

from -1.17

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.12M	15.22M	24.35M	25.98M	7.15M	-
Revenue Growth	-92.32%	1,258.57%	60.06%	6.69%	-72.50%	-100.00%
Gross Profit	-18.55M	-18.78M	-27.38M	-28.07M	-84.58M	-
Gross Margin	-1,656.25%	-123.43%	-112.44%	-108.04%	-1,183.74%	90.50%
Operating Income	-37.06M	-58.96M	-71.93M	-64.82M	-114.40M	-101.86M
Net Income	-110.09M	-60.51M	-65.77M	-63.69M	-20.60M	-97.00M
EPS	-	-	-	-	-1.74	-1.17
Free Cash Flow	-15.23M	-29.52M	-37.70M	-38.69M	-53.65M	-114.50M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-1.12
Avg	-1.17
Low	-1.21

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-